dr. bendell on remaining questions with regorafenib in hcc
Published 7 years ago • 105 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
2:36
prognostic value of metastatic sites in patients with mcrc treated with regorafenib
-
0:55
dr. bendell on exciting advancements in the field of hcc
-
1:03
dr. musher discusses the role of regorafenib in advanced hcc
-
5:53
redos trial: optimizing regorafenib dosing in metastatic colorectal cancer
-
1:35
dr. bruix discusses the success of regorafenib in hcc
-
3:24
'tumors just vanished': cancer patients now in remission after drug trial
-
2:27:40
sars-cov-2 origin: how we were misled and how molecular evidence imo proves it came from a lab
-
9:04
regorafenib - stivarga ®
-
3:48
clinical experience with regorafenib in hcc
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
0:49
dr. daniele on impact of regorafenib in hcc
-
1:49
regorafenib and pembrolizumab in pre-treated hepatocellular carcinoma
-
2:40
regorafenib plus pembrolizumab for first-line treatment of advanced hcc
-
0:58
managing colorectal cancer in patients who progress on regorafenib
-
4:07
80mg regorafenib plus pembrolizumab for 1l hcc
-
3:06
dr. finn on tivantinib and regorafenib for the treatment of liver cancer
-
2:04
dr. bruix on regorafenib in second-line hcc
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
1:34
dr. finn on the promise of regorafenib for the treatment of hcc